Memorial Sloan Kettering radiation oncologist Atif Khan

Atif Jalees Khan, MD, MS

Radiation Oncologist

Clinical Expertise

Radiation Therapy for Early and Advanced Breast Cancer, Primary and Secondary Brain Tumors; Brachytherapy; Proton Therapy; Stereotactic Cranial and Extracranial Radiotherapy

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Khan accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me

Education

MS, Radiological Sciences, Rush University - The Graduate College; MS, Clinical & Translational Science, Rutgers Graduate School of Biomedical Sciences; MD, Aga Khan University Medical College

Residencies

Rush University Medical Center

Fellowships

Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School

Board Certifications

Radiation Oncology

I am a radiation oncologist who specializes in caring for people with breast cancer, brain tumors, soft tissue sarcoma, skin cancer, and prostate cancer. I am experienced in using advanced treatment techniques, such as brachytherapy, proton therapy, and stereotactic radiation therapy. My experience allows me to offer the people I care for a plan that best suits their diagnosis and treatment goals.

Radiation oncology is in the middle of a technology revolution. We are creating new tools and techniques that can deliver treatment at a precise level we never could have imagined before. We have also come a long way in understanding the biology of various cancers. All of this means that many people with cancer have better outcomes with fewer side effects. I’m excited to be a part of this progress as a member of the Memorial Sloan Kettering team. MSK combines cutting-edge treatment and research with a history of excellence like no other.

I am heavily involved in clinical and translational research, particularly for breast cancer. Many of the studies I am currently leading are national and multi-institutional. These trials will fundamentally affect how we treat and think about breast cancer. I have also studied accelerated partial breast irradiation. This approach limits radiation to a tumor site, and it cuts down the number of treatment sessions, so patients don’t need to come to the clinic as often. I am also interested in how we can use drugs to make cancer cells more susceptible to the effects of radiation.

Receiving a diagnosis complicates the lives of people with cancer and their caregivers in many unanticipated ways. I experienced this firsthand when my mother was treated for breast cancer. I remember how much my parents valued her doctor’s time and having a personal connection as they navigated the unfamiliar world of hospitals and treatment centers. My experience with my family influences how I care for people with cancer, and I feel privileged to be a part of their lives. 

My experience with my family influences how I care for people with cancer, and I feel privileged to be a part of their lives.

Dr. Khan

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Haffty BG, Harrold E, Khan A, Pathare P, Ward BA, Matloff E, Alvarez-Franco M, Bale AE. (2002). Conservatively Managed Breast Cancer in Young Women: Outcome as a Function of BRCA 1/2 Status.  Lancet, 27;359(9316),1471-7.   

Khan AJ, Mehta PS, Zusag TW, Bonomi PD , Faber LP, Abrams RA.  (2006).  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastic, non-small cell lung carcinoma (NSLCL).  Radiother Oncol, 81(2),163-7.  

Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG.  (2011). Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor In Vitro and In Vivo.  Clinical Cancer Research, 17(7), 1807-14.

Khan AJ, Vicini FA, Brown S, Haffty BG, Kearney T, Dale R, Lyden M, and Arthur D.  (2013) Dosimetric Feasibility and Acute Toxicity in a Prospective Trial of Ultra-short Course Accelerated Partial Breast Irradiation (APBI) using a Multi-Lumen Balloon Brachytherapy Device.  Ann Surg Oncol.  20(4):1295-301.

Khan AJ, Rafique R, Zafar W, Shah C, Haffty BG, Vicini F, Jamshed A, Zhao Y.  (2017) Nation-Scale Adoption of Shorter Breast Radiotherapy Schedules Can Increase Survival in Resource Constrained Economies: Results from a Markov Chain Analysis. Int J Radiat Oncol Biol Phys. 97(2):287-295. doi: 10.1016/j.ijrobp.2016.10.002.  Pubmed PMID: 27986343.

Khan AJ, Poppe M, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG.  (2017) Hypofractionated Post-Mastectomy Radiation Therapy is Safe and Effective: First Results from a Prospective Phase II Trial.  J Clin Oncol.  In press.

Publications on PubMed

Visit PubMed for a full listing of Dr. Khan’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.